• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Fusion Pharmaceuticals Acquires IPN-1087

    Strata Oncology Unveils Strata PATH Trial

    Alimentiv Acquires McDougall Scientific

    Q BioMed Inks Strontium89 Supply Pact

    PCI Pharma Services Appoints SVP, CFO
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    WuXi AppTec Completes OXGENE Acquisition

    Celonic Group Announces Plans for New Facility in Switzerland

    BMS Expands Cell Therapy Manufacturing Capabilities

    Novo Nordisk Invests $80M in Tablet Production

    Arcline Investment Acquires ChargePoint Technology
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reshaping the Pharmaceutical Supply Chain

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Strata Oncology Unveils Strata PATH Trial

    Alimentiv Acquires McDougall Scientific

    WuXi AppTec Completes OXGENE Acquisition

    Live Webinar - Formulation Strategies for Poorly Soluble Molecules

    Celonic Group Announces Plans for New Facility in Switzerland
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    PCI Pharma Services

    Federal Equipment Company

    Emergent BioSolutions

    Alcami

    Syngene
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Syngene

    Reed-Lane

    Baxter BioPharma Solutions

    Alcami

    Adare Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Small-Molecule Drug Development: Advantages of an Integrated, Phase-Based Approach

    Small-molecule drug development has become more complex and challenging, leading to greater reliance on CDMOs.

    Small-Molecule Drug Development: Advantages of an Integrated, Phase-Based Approach
    Related CONTENT
    • Embedding Your Drug Strategy Within a Solid Foundation for Success
    • ERS Genomics Appoints IP & Commercial Development VP
    • PharmAbcine Partners with Samsung Biologics for PMC-403
    • Why is the sterility of your drug product much more than just a test of sterility?
    • Six Strategies to Stretch Your Limited Drug Supply for Clinical Studies
    Sarah Bethune, Cambrex09.09.20
    Small-molecule drug development has drastically advanced over the past three decades. Drug substances are more complex, manufacturing processes have become increasingly specialized, drug-delivery solutions are ever more sophisticated, and regulatory requirements have tightened to deliver a higher level of quality and efficacy to patients. Still, demand for safer, more efficacious, and cost-effective drug products continues to grow leading drug developers to increasingly outsource projects from early stage development through to clinical manufacture and commercial production.

    The emergence of the COVID-19 pandemic is further accelerating this trend. The depth of the role contract development and manufacturing organizations (CDMOs) play in supporting complex drug development challenges with sustainable solutions for the lifecycle of new drug development has evolved. Regardless of whether a drug manufacturer is a larger international industry leader or a small emerging specialty firm, ensuring business continuity throughout the entire lifetime of their small-molecule drug products is essential.

    The pathways for moving through development stages with a CDMO are not always intuitive, however. For the best possibility of success, drug developers should partner with a CDMO that has experience implementing a well-defined, phase-based approach to project execution beginning anywhere in the development cycle from early to later stages. This strategy allows for integrated, seamless progress via the development of processes that scale and transfer smoothly while maintaining project timelines.

    What is a phase-based approach?
    In a phase-based approach to small-molecule drug development, phases of a project are well-defined, documented, and understood by both the CDMO and the client. The goal is to ensure that projects only advance once all requirements of each phase are met. Taking this approach makes possible the integration of activities that support the progression of a new drug candidate from early stage to commercial launch and beyond, starting from the very beginning when a project is first evaluated to when it is “completed,” whatever form that might take.

    At Cambrex, small-molecule development projects are divided into the following phases:
    • Evaluation and Decision Phase
    • Planning Phase
    • Preparation Phase
    • Execution Phase
    • Assessment Phase
    • Post-execution Phase
    Going through the phases
    One of the first benefits of a phase-based approach, particularly for virtual companies with little if any knowledge of the drug-development process, is having a clear understanding of where/how a project begins. The Evaluation and Decision Phase provides the needed clarity and is initiated with a request for proposal from the potential client.

    During this phase, there is extensive contact with the client, including in-depth discussion about the project objectives. It begins at Cambrex with information gathering and the performance of a feasibility check. This process is followed by a site-selection process, during which the optimum location within Cambrex’s international network of R&D and production facilities is identified. The ultimate outcome of this phase is the development and acceptance of a work proposal.

    In the Planning Phase, the signed proposal is in hand and movement on the project begins with the establishment of a project team and development of the initial project plan. Knowing the objectives and scope of the project, a proposed timeline and initial execution strategy are agreed upon with the client at the project kick-off meeting. The project plan is outlined based on the team and resources and is finalized into a scope of work once all key issues have been addressed.

    With the initial plan in hand, the Preparation Phase can begin. The key goal during this phase is to achieve risk mitigation. All documentation needed to support the project is initiated, particularly documents that support GMP-related requirements, such as management of change, and other project governance materials such as development reports.

    Governing processes are also established, raw materials procured, and initial analytical methods and any existing manufacturing process and chemistry/formulation development information transferred to Cambrex from the client. As appropriate based on the phase of development, a quality risk matrix is developed to establish a risk-mitigation strategy.

    Process development and manufacturing work begins in the Execution Phase. All information is recorded in the appropriate notebooks depending on the phase of development—lab; pilot plant; clinical manufacturing for phase 1, 2 or 3 trials; formulation development; validation production batches; etc.

    The Assessment Phase, which comes next, often takes the longest time to complete. Once all the batches have been produced and all the data generated, it is essential to determine the meaning of those results which guides next steps and decisions. This goal is achieved through generation of documents necessary to close out the project, such as regulatory documentation (e.g. demonstration of successful validation and to support relevant filing requirements) and tech transfer reports.

    Equally important is the evaluation of the risk-mitigation strategy, including identification of any realized risks. It must be determined if any issues have arisen that would require a project to be sent back to an earlier phase due to quality or other technical concerns.

    The final Post-Execution Phase is critical because conclusions are drawn about performance throughout the other phases of the project. The entire team participates in a discussion of the lessons learned that can be applied to future projects. Depending on the phase of development, a full risk-mitigation summary is completed to document the process. Projects in the early stage of drug development can still assess challenges that may have occurred, and the team can present suggested next steps in final development reports.

    At this point, the project is “completed” and ready to pass to new ownership, whether that means progression to the supply of clinical materials or transfer to another production site within Cambrex for commercial production. There is, therefore, also a future-oriented aspect to this phase, in which the strategy for moving on is identified.

    Mitigating challenges
    Even with a well-defined, phase-based approach to small-molecule drug development, challenges can still arise. Most often these occur in the Preparation and Assessment Phases, and knowing this, the Cambrex team pays special attention to mitigating challenges in these phases.

    For later stage projects, during the Preparation Phase, it is essential to identify all relevant risks and develop adequate mitigation strategies to minimize those risks. Development of appropriate documentation and testing is also essential to ensure that all the information needed to make the right decisions with respect to the risk mitigation strategy has been provided. The likelihood that quality or other problems will arise and be identified in the Assessment Phase increases dramatically if the Preparation Phase is not properly implemented. As a result, a project can be kicked back to the Preparation Phase rather than moving on to the Post-Execution Phase.

    In the Assessment Phase, inappropriate or incomplete evaluation of what occurred in the Execution Phase can also hinder or stall a project. Improper assessment of outstanding risks is particularly problematic. During later stage projects, it is essential to determine if risks were adequately addressed and if not, why not, and whether there are any remaining risks going forward.
    Quality risks such as degradation/stability and dissolution issues that are realized can, for instance, require a project to return to the Preparation Phase where steps will be taken to recover from the problem.

    The value of Quality Risk Management
    For customers progressing to later stage of drug development, Cambrex can assist in applying a quality risk management process in the Preparation Phase where all relevant potential risks across the entire project—not just the process or formulation—are identified and a comprehensive risk management strategy developed in collaboration with our customers. In addition to the more traditional technical risk matrix that looks at the process, equipment, etc., an administrative quality risk matrix is developed that considers all other project-related risks, such as difficult-to-find raw materials and other supply chain, logistics and support-team-related issues.

    Risks are identified as low, medium, or high. Most tend to be low, but there are typically some that are classified as medium or high. All risks are recommended to be evaluated, rated, and mitigated, as appropriate.

    In the Assessment Phase, Cambrex focuses on closing out the technical and administrative quality risk matrices. Both are rescored based on the data collected in the Execution Phase. Regardless of the scoring level, Cambrex collaborates with its customers to ensure risks are not overlooked.  In addition, Cambrex ensures that all reports and regulatory documentation are closed out with the risk matrix in support of moving to the Post-Execution Phase.

    Cyclical process
    Indeed, Cambrex’s phase-based approach to small-molecule drug development project execution is a cyclical process. At any given time, a project can be evaluated with respect to achieving its objectives and deliverables. This affords Cambrex the ability to support customers with a well-defined process, and pivot at any point, whether for the purpose of improving efficiency/productivity or due to the need to meet new regulatory requirements.

    This well-defined and cyclical phase-based approach makes it possible for Cambrex and our customers to clearly identify the status of each every small-molecule drug-development project and what needs to be done next. Every project manager can tell the customer exactly what phase the project is in at any point so that customers are always fully integrated into the project.
    Outcomes and completion criteria are reliable with this detail-oriented approach. Cambrex understands the drug development cycle and has years of expertise at every stage, allowing us to efficiently recognize opportunities to benefit our customers. 

    Built on a foundation of trust
    Transparency and communication are critical to the success of Cambrex’s phase-based approach to small-molecule drug development. Team-wide discussions take place at routine project team meetings where customers have a consistent project manager serving as the main contact. Direct communication lines are also established to technical experts at Cambrex to ensure that critical information can be shared in real time.

    Given the current travel restrictions and social-distancing requirements resulting from the COVID-19 pandemic, Cambrex is offering extensive virtual communication systems, from basic online meetings to virtual viewing of in-plant operations. An emphasis on collaboration through established communication pathways with a commitment to transparency solidifies partnerships and builds customer trust. 
    Related Searches
    • Drug Development
    Suggested For You
    Embedding Your Drug Strategy Within a Solid Foundation for Success Embedding Your Drug Strategy Within a Solid Foundation for Success
    ERS Genomics Appoints IP & Commercial Development VP ERS Genomics Appoints IP & Commercial Development VP
    PharmAbcine Partners with Samsung Biologics for PMC-403 PharmAbcine Partners with Samsung Biologics for PMC-403
    Why is the sterility of your drug product much more than just a test of sterility? Why is the sterility of your drug product much more than just a test of sterility?
    Six Strategies to Stretch Your Limited Drug Supply for Clinical Studies Six Strategies to Stretch Your Limited Drug Supply for Clinical Studies
    Vectura and Monash University Support Development of Inhaled Oxytocin Vectura and Monash University Support Development of Inhaled Oxytocin
    GigaGen Initiates Large-Scale Manufacturing of GIGA-2050 GigaGen Initiates Large-Scale Manufacturing of GIGA-2050
    Cobra Biologics and CombiGene Partner Cobra Biologics and CombiGene Partner
    Preclinical Planning for Successful Drug Development Preclinical Planning for Successful Drug Development
    Piramal to Deliver Integrated Services to Epirium Piramal to Deliver Integrated Services to Epirium
    Drug Safety and Pharmacovigilance: Effective Drug Safety Reporting and Surveillance Drug Safety and Pharmacovigilance: Effective Drug Safety Reporting and Surveillance
    Evotec and Novo Nordisk Form Strategic Alliance Evotec and Novo Nordisk Form Strategic Alliance
    RedHill and Cosmo Pharmaceuticals Expand Strategic Partnership RedHill and Cosmo Pharmaceuticals Expand Strategic Partnership
    Avacta Appoints Chief Development Officer Avacta Appoints Chief Development Officer
    CoreRx Fully Operational in New Product Development Center CoreRx Fully Operational in New Product Development Center

    Related Features

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20

    • Drug Development | Drug Discovery | R&D
      R&D Outsourcing Trends

      R&D Outsourcing Trends

      Highly specialized drug products and capacity needs drive increased reliance on contract service providers.
      Kristin Brooks, Managing Editor, Contract Pharma 10.14.20

    • Drug Development | Preclinical Outsourcing
      Preclinical Planning for Successful Drug Development

      Preclinical Planning for Successful Drug Development

      When the preclinical pressure is on, appropriate planning can make sure timelines are achievable.
      Mingyi Trimble, WuXi AppTec 09.09.20


    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Managing Editor 09.09.20

    • Drug Development | Regulatory Affairs
      Guidelines in Toxicology: A Blessing and a Curse

      Guidelines in Toxicology: A Blessing and a Curse

      A look at the evolution of drug development regulatory guides.
      Sarah Gould, Senior Principal Scientific Advisor, Charles River 09.16.19

    • Drug Development
      Flex Your Outsourcing Model to Maximize Drug Development

      Flex Your Outsourcing Model to Maximize Drug Development

      How to choose—and optimize—combinations of service models to fit your needs.
      Timothy King, Executive Director, Functional Service Partnerships (FSP), PPD 09.16.19


    • Biologics, Proteins, Vaccines | Drug Delivery | Drug Development
      Knowledge Sharing: Biologics Development and Delivery

      Knowledge Sharing: Biologics Development and Delivery

      The increasing importance of sharing information to build awareness and better manage the complexities of drug development.
      Fran L. DeGrazio, Vice President of Scientific Affairs and Technical Services, West Pharmaceutical Services 09.16.19

    • Drug Development
      Improving Your Development Program

      Improving Your Development Program

      Seven lab science trends driving the future of drug development.
      Jenifer Vija, Liam Moran, Chris Loosbroock and Eric Snyder, Charles River 05.07.19

    • Drug Development
      Technical Advantages of Continuous Flow Chemical Synthesis

      Technical Advantages of Continuous Flow Chemical Synthesis

      Continuous flow chemistry is known for its ability to handle hazardous reactions safely, but can also unlock many other technological benefits.
      Shawn Conway, Engineering R&D Director, Cambrex High Point 04.05.19


    • Drug Development | Preclinical Outsourcing
      Early Development Trends

      Early Development Trends

      Catalent’s president of oral drug delivery, Jonathan Arnold, talks trends and challenges in the early phases of drug development.
      Tim Wright, Editor, Contract Pharma 03.06.19

    • Drug Development
      Future Trends in the CDMO Space

      Future Trends in the CDMO Space

      And how to navigate them for successful drug development
      Guillaume Plane, Global Development and Marketing Manager, BioReliance End-to-End Solutions, MilliporeSigma 01.25.19

    • APIs | Cytotoxics and High Potency Manufacturing | Drug Development
      CDMOs On The Rise

      CDMOs On The Rise

      Tracking growth and strategies in the CDMO business
      Michel Le Bars, Managing Partner, Kurmann Partners AGe 01.25.19


    • Drug Development | Formulation Development
      Abuse Deterrent Formulations

      Abuse Deterrent Formulations

      A look at opioid abuse in North America and formulations to help avoid an epidemic.
      Damon Smith, Richard Dart and Christopher Hirst 11.13.18

    • Drug Development
      Streamlining Drug Development:

      Streamlining Drug Development:

      Four key takeaways from Veeva’s 2018 R&D Summit
      Henry Levy, General Manager of Vault CDMS, Veeva Systems 11.13.18

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Haste Makes Waste

      Haste Makes Waste

      When to sprint and when to breathe in the race from lab to clinic.
      Christian Cattaruzza, MilliporeSigma 09.11.18

    Trending
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • AbbVie Opts To Acquire Mitokinin
    • Bormioli Opens New Glass Research Center
    • Arcline Investment Acquires ChargePoint Technology
    • Spark Therapeutics Appoints CTO
    Breaking News
    • Fusion Pharmaceuticals Acquires IPN-1087
    • Strata Oncology Unveils Strata PATH Trial
    • Alimentiv Acquires McDougall Scientific
    • Q BioMed Inks Strontium89 Supply Pact
    • PCI Pharma Services Appoints SVP, CFO
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Low Levels of Vitamin D and Calcium Linked to COVID-19 Severity
    Probiotic Evidenced to Assist Digestive Recovery from a Complex Surgery
    AHPA Submits Comments to FDA on Proposed Traceability Rule
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    AOC Announces EMEA Price Increase
    Mule-Hide Products Co. Introduces Seal-Fast Liqui-Flash
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    NAMSA Acquires American Preclinical Services
    Quidel's QuickVue At-Home COVID-19 Test Earns EUA
    Memic Receives FDA Marketing Authorization for Hominis
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Fusion Pharmaceuticals Acquires IPN-1087
    Strata Oncology Unveils Strata PATH Trial
    Alimentiv Acquires McDougall Scientific
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    IT Cosmetics Supports Women’s Confidence
    Inter Parfums Reports a Strong Fourth Quarter
    Universal Engraving Announces New President
    Happi

    Latest Breaking News From Happi

    Croda International Acquires Alban Muller
    Givaudan Active Beauty Launches Omegablue
    Sozio Acquires Scentessence
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Abbott Label installs Domino K600i dual bar digital UV inkjet printer
    Crossmark turns to Eagle Systems for cold foil
    Maxcess launches Tidland PressureMax Airshaft Pressure Monitoring System
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Domtar Completes Sale of Personal Care Business
    Mitsui to Sell Chinese Nonwovens Business
    Dr. J's Disinfectant Wipes Approved for Distribution in CA
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    FDA Approves Accufix Surgical's Accu-Joint Hemi Implant
    FDA OKs Q-Collar Device to Protect Athletes’ Brains During Head Impacts
    SeaSpine Releases Reef TO (TLIF Oblique) Interbody System
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login